EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular docking to homology models of human and Trypanosoma brucei ERK8 that identified ortholog-specific inhibitors

Matthew Merski, Zachary B Mackey iD

PLOS Neglected Tropical Diseases · 2025

DOI: 10.1371/journal.pntd.0013487 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, 2025. Verfasst von Matthew Merski und 1 weiteren Autor:innen. Beteiligte Einrichtung: i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal. Hauptthemen laut MEDLINE: Trypanosoma brucei brucei, Trypanocidal Agents, Protozoan Proteins, Extracellular Signal-Regulated MAP Kinases. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human African Trypanosomiasis (HAT), also known as sleeping sickness, is a lethal disease caused by two vector-borne parasites: Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense . The limited number of antitrypanosomal therapies for treating these deadly parasites suffer from toxicity, poor efficacy, and unspecified targets; thus, more and better medicines are needed. We used in silico methods to predict features of the bioactive compound AZ960 that make it an ortholog-specific inhibitor for the extracellular-signal regulated kinase 8 of T. brucei (TbERK8). Our homology models showed that the TbERK8 ATP binding pocket was smaller and more hydrophobic than that of human ERK8 (HsERK8). Molecular docking studies predicted six FDA-approved compounds that would be orthologue-specific inhibitors of HsERK8 or TbERK8. Experimental testing of these compounds identified prednisolone as an HsERK8-specific inhibitor. Sildenafil inhibited TbERK8, as predicted by our binding model. Its impact on TbERK8 activity supports our hypothesis that designing compounds that can exploit differences in the orthologs as buildable scaffolds and expand the repertoire of ortholog-specific antitrypanosomal agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Trypanosoma brucei bruceiTrypanocidal AgentsProtozoan ProteinsExtracellular Signal-Regulated MAP KinasesProtein Kinase InhibitorsHumansMolecular Docking SimulationTrypanosomiasis, African

Substanzen

Trypanocidal AgentsProtozoan ProteinsExtracellular Signal-Regulated MAP KinasesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
  • IBMC - Instituto de Biologia Molecular Celular, Universidade do Porto, Porto, Portugal.
  • Institute for Evolution and Biodiversity, University of Münster, Münster, Germany.
  • Department of Biochemistry, Virginia Tech, Blacksburg, Virginia, United States of America.
  • Virginia Tech Center for Drug Discovery, Virginia Tech, Blacksburg, Virginia, United States of America.

ORCID-Profile: Zachary B Mackey

Förderung

  • National Science Foundation

Zitieren

APA

Merski, M., & Mackey, Z. B. (2025). Molecular docking to homology models of human and Trypanosoma brucei ERK8 that identified ortholog-specific inhibitors. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0013487

Vancouver

Merski M, Mackey ZB. Molecular docking to homology models of human and Trypanosoma brucei ERK8 that identified ortholog-specific inhibitors. PLOS Neglected Tropical Diseases. 2025. doi:10.1371/journal.pntd.0013487

BibTeX
@article{Merski2025,
  author = {Merski, Matthew and Mackey, Zachary B},
  title = {Molecular docking to homology models of human and Trypanosoma brucei ERK8 that identified ortholog-specific inhibitors},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2025},
  doi = {10.1371/journal.pntd.0013487}
}
Kostenlos starten →